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Background: The KRAS oncogene was one of the earliest discoveries of genetic alterations in colorectal and lung
cancers. Moreover, KRAS somatic mutations might be used for predicting the efficiency of anti-EGFR therapeutic
drugs. The purpose of this research was to improve Activating KRAS Detection Chip by using a weighted enzymatic
chip array (WEnCA) platform to detect activated KRAS mutations status in the peripheral blood of non-small-cell
lung cancer (NSCLC) and colorectal cancer (CRC) patients in Taiwan.
Methods: Our laboratory developed an Activating KRAS Detection Chip and a WEnCA technique that can detect
activated KRAS mutation status by screening circulating cancer cells in the surrounding bloodstream. We collected
390 peripheral blood samples of NSCLC patients (n = 210) and CRC patients (n = 180) to evaluate clinical KRAS
activation using this gene array diagnosis apparatus, an Activating KRAS Detection Chip and a WEnCA technique.
Subsequently, we prospectively enrolled 88 stage III CRC patients who received adjuvant FOLFOX-4 chemotherapy
with or without cetuximab. We compared the chip results of preoperative blood specimens and their relationship
with disease control status in these patients.
Results: After statistical analysis, the sensitivity of WEnCA was found to be 93%, and the specificity was found to be
94%. Relapse status and chip results among the stage III CRC patients receiving FOLFOX-4 plus cetuximab (n = 59)
and those receiving FOLFOX-4 alone (n = 29) were compared. Among the 51 stage III CRC patients with chip
negative results who were treated with FOLFOX-4 plus cetuximab chemotherapy, the relapse rate was 33.3%;
otherwise, the relapse rate was 48.5% among the 23 out of 88 patients with chip negative results who received
FOLFOX-4 alone. Negative chip results were significantly associated to better treatment outcomes in the FOLFOX-4
plus cetuximab group (P = 0.047).
Conclusions: The results demonstrated that the WEnCA technique is a sensitive and convenient technique that
produces easy-to-interpret results for detecting activated KRAS from the peripheral blood of cancer patients. We
suggest that the WEnCA technique is also a potential tool for predicting responses in CRC patients following
FOLFOX-4 plus cetuximab chemotherapy.
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Ras proteins, which play a key role in cell growth, apop-
tosis, motility, and differentiation, are low molecular
weight (21 kD) GTPases that cycle between the GDP-
bound (inactive) and the GTP-bound (active) states at
the plasma membrane [1,2] and bind to and activate a
plethora of downstream effector proteins, including
Raf kinases, phosphatidylinositol 3-kinases (PI3-K), and
RalGDS family members [3–5]. The activation of mutations
of the ras family is among the most common genetic events
of human tumorigenesis [6]. Constitutive activations of the
three canonical family members—K-ras, N-ras, and H-ras
are segregated strongly by tissue type [7]. Of these, KRAS
mutations are the most common in human tumors, includ-
ing those arising from the colon and lungs [8]. In our previ-
ous research analysis of the KRAS mutation of lung cancer,
colorectal cancer (CRC), and adrenocortical cancer, the
mutation rates of these cancer tissues were found to be
37%, 26%, and 45%, respectively [9–14]. The frequency of
KRAS mutations across a broad range of human tumors
suggests the potency of the oncogenic contribution of the
constitutively active form of this protein.
In recent years, due to rapid developments in targeted
therapies, numerous monoclonal antibodies and molecu-
lar drugs that have been developed and applied clinically,
such as Iressa and Cetuximab. Many reports show that
KRAS mutations are highly specific negative predictors
of response to epidermal growth factor receptor-tyrosine
kinase inhibitors (EGFR-TKIs) monotherapy in advanced
non-small-cell lung cancer (NSCLC) and similarity to
anti-EGFR monoclonal antibodies alone or in combination
with chemotherapy in metastatic colorectal cancer (mCRC)
[15–18]. Therefore, the efficient, accurate, and fast analysis
for detecting KRAS mutations status in cancer patients
before selecting such type of targeted therapy is con-
sidered quite important.
So far, therapeutic targets such as HER2/neu, EGFR,
KRAS, and BRAF are analyzed using polymerase chain
reaction (PCR) combining direct sequencing, fluores-
cence in situ hybridization (FISH), real-time PCR, and
other methods. These methods have disadvantages, such
as inadequate sensitivity and the need to collect patients’
cancer tissues as a specimen, which make medicinal-effect
evaluations prior to clinical treatment difficult. When the
tumor size is too small, when the tumor has been removed
by resection, or when the tumor has metastasized, no
tumor tissues can be obtained for such analyses. In previous
studies, we successfully constructed the Activating KRAS
Detection Chip for detecting KRAS activation from periph-
eral blood, and demonstrated that there was a high level of
correlation between activating KRAS and KRAS mutations
[10,19]. Since the target genes on the chip were originally
selected from a microarray which had been used to distin-
guish between adrenocortical tumor tissues with mutantKRAS and normal controls [19], and since the detection
accuracy was validated as 93.85% in that study, the chip is
reasonably referred to as KRAS detection chip. On the
other hand, a correlation between KRAS mutations and
poor responses to EGFR targeted treatment was also
found [20,21]. For this reason, the detection of activating
KRAS could be used to predict the response to EGFR tar-
geted treatment.
Although this technique provides a convenient way
of using peripheral blood directly for detecting KRAS
activation and has achieved major breakthroughs in
clinical applications, its sensitivity is only approxi-
mately 84% [19]. The aim of this research is to improve
this technique by using a weighted enzymatic chip
array (WEnCA) platform (Figure 1), in which the
weighted scores are added according to the relevance
of each gene to activating KRAS mutations. The 22
candidate genes on the Activating KRAS Detection
Chip are given different weighted values, based on the
performance after KRAS activation, in order to develop
a detection platform that is more sensitive, accurate,
and easier to read than the former technique that did
not include weighted calculation which was also estab-
lished by our research team [22]. The weighted calcula-
tions of genes on the Activating KRAS Detection Chip
simplify the interpretation of results, due to the wid-
ened gap between the positive and negative results. In
the current study, we collected 390 peripheral blood
samples from NSCLC and CRC patients to evaluate
their clinical KRAS activation using the WEnCA tech-
nique to analyze the sensitivity, specificity, and diag-
nostic accuracy of WEnCA. In advance, we analyzed
the correlations among relapse status, chemotherapy
(oxaliplatin, folinic acid, and fluorouracil (FOLFOX-4)
chemotherapy) plus cetuximab status and chip results
for 88 patients with Union for International Cancer
Control (UICC) stage III CRC. The results provided
evidence that using the Activating KRAS Detection
Chip in clinical contexts has the potential to increase
the accuracy of chemotherapy efficacy predictions for




Initially, cancerous tissues from 390 randomly selected
cancer patients, including 210 NSCLC patients and 180
CRC patients, were enrolled into this study. The data of
these 390 cancer patients were used to analyze the sensi-
tivity, specificity, and diagnostic accuracy of WEnCA.
Furthermore, we enrolled 88 stage III CRC patients to
investigate the clinical application of chip results and
their correlations with CRC relapse status in patients re-
ceiving FOLFOX-4 plus cetuximab or FOLFOX-4 alone.
Figure 1 The operating procedure of weighted enzymatic chip array (WEnCA). The operating procedure of weighted enzymatic chip array
(WEnCA) includes RNA purification by magnetic beads, cDNA labeling with Biotin, enzymatic chromogenic reaction, and weighted calculation for
result interpretation of the chip.
Huang et al. Journal of Translational Medicine 2014, 12:147 Page 3 of 9
http://www.translational-medicine.com/content/12/1/147Cancerous tissues and corresponding preoperative
peripheral blood samples (5 ml) from 210 randomized
NSCLC patients and 180 randomized CRC patients
undergoing radical resection were investigated using
WEnCA. All of these patients had undergone surgical
resection, with NSCLC and CRC pathologies diagnosed
in two hospitals, including Fooyin University Hospital
and Kaohsiung Medical University Hospital. To avoid
the contamination of skin cells, blood samples were
taken through an intravenous catheter before surgery,
and the first few milliliters of blood were discarded. Total
RNA was immediately extracted from the peripheral whole
blood and then served as templates for complementary
DNA (cDNA) synthesis. Tissue specimens were collected
immediately after surgical resection, frozen instantly in
liquid nitrogen, and stored in a freezer at −80°C until
analysis. Sample acquisition and use were approved by
the Institutional Review Boards of the two hospitals.
Moreover, we included 88 stage III CRC patients who
were treated postoperatively with adjuvant FOLFOX-4
plus cetuximab or with FOLFOX-4 chemotherapy only.
The FOLFOX-4 plus cetuximab regimen consisted of bi-
weekly cetuximab at a dose of 500 mg/m2 in a two-hour
infusion, followed by FOLFOX-4 chemotherapy on day 1
of a 14-day cycle. The FOLFOX-4 treatment consisted of
85 mg/m2 of oxaliplatin concurrent with 200 mg/m2 of
leucovorin, both as a two-hour infusion on day 1, followed
by a 400 mg/m2 bolus of 5-FU and a continuous infu-
sion of 600 mg/m2 of 5-FU over 22 -hours, was repeated
every 2 weeks for 12 cycles in total. Postoperative
surveillance consisted of a medical history, physical
examination, and laboratory studies every 3 months.Abdominal ultrasonography or CT was performed every
3 months during chemotherapy. After the chemotherapy
was completed, abdominal ultrasonography or CT was
performed every 6 months. Chest radiography and a
total colonoscopy were performed once a year. The en-
rolled patients were followed up at 3-month intervals
for 2 years and at 6-month intervals thereafter. Relapse
was defined as any local recurrence or distant metasta-
ses within 36 months after the adjuvant chemotherapy.
Then, we compared those blood specimen chip results
with the relapse status for these patients.
DNA extraction and direct sequencing
Genomic DNA was isolated from the surgically resected
primary tumor tissues using a proteinase-K (Stratagene,
La Jolla, CA, USA) digestion and phenol/chloroform
extraction procedure, according to the method of Sambrook
[23]. To identify mutations of the KRAS genes in cancerous
tissues, polymerase chain reaction (PCR) analysis was
performed. The oligonucleotide primers for KRAS exons
1 and 2 were used (Table 1). Briefly, the PCR amplification
of DNA samples (20 ng) was performed in a 50 ul reaction
volume with a final concentration of 19 PCR buffer
[10 mmol/l Tris–HCl (pH 8.3), 1.5 mmol/l MgCl2,
50 mmol/l KCl, and 0.01% gelatin], 100 mmol/l deoxy-
nucleotide triphosphate (Promega), and 5 U (1 U/ul)
BioTools DNA polymerase (Biotechnological and Medical
Laboratories, S.A., Madrid, Spain) for each reaction. The
PCR products were purified by a QIAEX II gel extraction
kit (Qiagen Inc., Valencia, CA, USA) and then subjected
to sequencing using a double-stranded cycle sequencing
system (Gibco-BRL, MD, USA). The purified products were
Table 1 Nucleotide sequences of oligonucleotide primers used for PCR and sequencing of KRAS
Sequences PCR product (bp)
Gene Exon Forward primer (5′→ 3′) Reverse primer (5′→ 3′)
KRAS 1 TAATACGACTCACTATAGGGAGATATGTTGAGGGCCCATCTCTC TCCTAGGTCAGCGCAACCAAAT 131
KRAS 2 TAATACGACTCACTATAGGGTTCCTACAGGAAGCAAGTAG CACAAAGAAAGCCCTCCCCA 148
Sequencing primer CCCTATAGTGAGTCGTATTA
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(LI-COR, Lincoln, NE, USA), which is a T7 promoter
primer (Table 1) labelled with a heptamethine cyanine
dye, using DNA polymerase incorporating infrared
fluorochrome (IRD)-labelled dATP for sequencing reaction.
To detect and analyse the sequencing ladder, an automated
DNA electrophoresis system (Model 4200; LICOR) with a
laser diode emitting at 785 nm and fluorescence detection
between 815 and 835 nm was used. Following the loading
of samples, electrophoresis was executed at a constant
voltage of 2,000 V with the gel heated to 50°C. Data
collection and image analysis were performed using an
IBM486 (Model 90) with the Base Image IR software
supplied with the model 4200 DNA sequencer.
Total RNA extraction and first strand cDNA synthesis
Total RNA was extracted from the fresh whole blood of
cancer patients using the GeneCling® Enzymatic Gene Chip
Detection Kit (MedicoGene Biotechnology Co., Ltd., Los
Angeles, CA, USA). Purified RNA was quantified by OD
260 nm using an ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA) and quantitated by
Bioanalyzer 2100 (Agilent Technologies, USA). First-strand
cDNA was synthesized from total RNA using a GeneCling®
Enzymatic Gene Chip Detection Kit. Reverse transcrip-
tion was performed in a reaction mixture consisting of
a 3 μg/ml oligo (dT) 18-mer primer, 1 μg/ml random
6-mer primer, 100 mmol/l deoxyribonucleotide triphos-
phate, 200 units of Reverse Transcriptase MMLV, and 25
units of ribonuclease inhibitor. The reaction mixtures with
RNA were incubated at 42°C for a minimum of 2 h, heated
to 95°C for 5 min, and then stored at −80°C until analysis.
Preparation of activating KRAS detection chip
The procedure of the membrane-array method for gene
detection was performed based on our previous study [19].
Visual OMP3 (Oligonucleotide Modeling Platform, DNA
Software, Ann Arbor, MI, USA) was used to design probes
for target genes and β-actin. The oligonucleotide sequences
of 22 target genes for Activating KRAS Detection Chip are
listed in Table 2. The newly synthesized oligonucleotide
fragments were dissolved in distilled water to a concen-
tration of 100 mM, and applied to a BioJet Plus 3000 nL
dispensing system (BioDot Inc., Irvine, CA, USA), which
blotted the target oligonucleotide; the β-actin control was
used sequentially (0.05 μL per spot and 1.5 mm betweenspots) on a SuPerCharge nylon membrane (Schleicher and
Schuell, Dassel, Germany) in triplicate. After rapid drying
and cross-linking procedures, the preparation of the
membrane array was completed. The expression levels of
each gene spot measured by the WEnCA method were
quantified and then normalized based on reference gene
(β-actin) density. We have defined as an overexpressed
gene spot as a case wherein the observed normalized spot
density was 2 or more.
Preparation of Biotin-labeled cDNA targets and hybridization
First-strand cDNA were applied for biotin labeling, and the
biotin labeled probes then hybridized with the Activating
KRAS Detection Chip. The hybridized chip followed wash-
ing, blocking and color development procedures using a
GeneCling® Enzymatic Gene Chip Detection Kit. The hy-
bridized arrays were then scanned with an Epson Perfection
1670 flatbed scanner (SEIKO EPSON Corp., Nagano-ken,
Japan). Subsequent quantification analysis of the intensity
of each spot was executed using AlphaEase® FC software
(Alpha Innotech Corp., San Leandro, CA, USA). Spots con-
sistently carrying a factor of two or more were considered
to be differentially expressed. A deformable template ex-
tracted the gene spots and quantified their expression levels
by determining the integrated intensity of each spot after
background subtraction. The fold ratio for each gene was
calculated as follows: spot intensity ratio =mean intensity
of target gene / mean intensity of β-actin. Figure 2 provides
the schematic representation of the membrane array
with 22 candidate genes, one positive control (β-actin), one
negative control (Oryza sativa sequence), and the blank
control (dd water). As the concentration of β-actin was di-
luted 10–20 fold diluted for spotting, it would only present
the medial-low expression level. According to the proced-
ure, the chromogenic reaction was stopped depending on
the appearance of the strongest spots; thus, the expression
of β-actin on each chip would not be the same even
under a longer chromogenic development procedure.
Since β-actin acted as the internal control on each chip,
all the other spots were then normalized based on the
density of β-actin to reduce the individual differences.
Chip interpretation (WEnCA method)
A deformable template extracted the gene spots and
quantified their expression levels by determining the inte-
grated intensity of each spot after background subtraction.
Table 2 Oligonucleotide sequences of target genes
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reference gene (β-actin) density as follows: spot intensity
ratio = mean intensity of target gene/mean intensity of
β-actin. Normalized spot density carrying a factor of 2
or more was considered to be a differentially overexpressed
gene. Each overexpressed spot was then multiplied by
respective weighted values ranging from 1 to 4 based on
the performance after KRAS activation to calculate the total
score of the chip. When the total score was higher than
cutoff value 20 which was determined through Receiver
Operating Characteristic (ROC) Curve in our previous
study, the chip was defined as positive result [22].
Statistical and database analysis
All statistical analyses were performed using the Statistical
Package for the Social Sciences version 18.0 (SPSS, Inc.,
Chicago, IL, USA). A chi-square test was used to analyze
the association between WEnCA and direct sequencing for
activated KRAS detection in peripheral blood and tumor
tissues. The sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV) and accuracy of the
WEnCA platform were evaluated. The chip results and the
clinical pathological features of NSCLC and CRC patients,
and the relapse status and cetuximab medication statusbetween the two groups (positive chip result versus negative
chip result) were compared using chi-square test. A p-value
of less than 0.05 was considered statistically significant.
Results
Clinicopathological features of cancer patients
We used data from a sample consisting of 206 men (52.8%)
and 184 women (47.2%). The mean age was 64 years
(range 37–87 years) for the 210 NSCLC patients and
65 years (range 29–79 years) for the 180 CRC patients.
The clinicopathologic characteristics of these cancer
patients are listed in Table 3; 202 patients were subse-
quently diagnosed with stage I-II cancers, and 188 were
subsequently diagnosed with stage III-IV cancers.
The association between WEnCA and direct sequencing
for activated KRAS detection in peripheral blood and
tumor tissues
To establish the capabilities of the WEnCA platform
for the clinical detection of KRAS activation in blood
samples, we collected 390 samples of peripheral blood
from pathology-proven NSCLC and CRC patients. All
specimens were tested with the Activating KRAS Detec-
tion Chip using the WEnCA method (Table 4). The paired
Figure 2 The schematic representation of an Activating KRAS Detection Chip and the analytic results in the peripheral blood
specimen. (A) The schematic representation of an Activating KRAS Detection Chip with 22 candidate genes, one positive control (β-actin), one
negative control (Oryza sativa sequence), and the blank control (dd water). Oligonucleotide fragments are blotted on membranes in triplicate.
The expression levels of each gene spot were quantified and then normalized based on reference gene (β-actin) density which the spots are
within the red circle of each image. We defined an overexpressed gene spot when the normalized spot density was 2 or more. Each overexpressed
spot was then multiplied by respective weighted values ranging from 1 to 4 based on the performance after KRAS activation to calculate the total
score of the chip. When the total score was higher than cutoff value 20, the chip result were considered to be positive. (B) Detectable KRAS oncogene
from circulating RNA in the peripheral blood. (C) Undetectable KRAS oncogene from circulating RNA in the peripheral blood.
Table 3 Clinicopathologic characteristics of 210
non-small-cell lung cancer patients and 180 colorectal
cancer patients
Lung cancer Colorectal cancer
Variables number (%) number (%)
Gender
Male 112 (53.3) 94 (52.2)
Female 98 (46.7) 86 (47.8)
Age (years)
<65 115 (54.8) 85 (47.2)
≥65 95 (45.2) 95 (52.8)
Stage (AICC)a
I + II 109 (51.9) 93 (51.7)
III + IV 101 (48.1) 87 (48.3)
T stage
T1 + T2 149 (70.9) 44 (24.4)
T3 + T4 61 (29.1) 136 (75.6)
Lymph node metastasis
No 94 (44.8) 93 (51.7)
Yes 116 (55.2) 87 (48.3)
aAmerican Joint Committee on Cancer.
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mutational status by direct sequencing. There were
127 cancer tissues with KRAS mutants. The mutation
sites are distributed in codon 12, 13, 15, 18, 31, and 60.
Among them, 117 were positive through WEnCA. More-
over, among the 263 paired cancer tissues with wild type
KRAS, 249 were negative through WEnCA. After statistical
analysis, the sensitivity, specificity, PPV, NPV and accur-
acy of WEnCA were 92.13%, 94.68%, 89.31%, 96.14%
and 93.85%, respectively (p <0.001).
The association between the calculation results of WEnCA
and the clinicopathological features
The mean positive gene number and the mean total
score of the positive chip by WEnCA associated signifi-
cantly with the AJCC stage, T stage, and distant metastasis
(p <0.05) (Table 5).
The association between clinical relapse status and
WEnCA results in stage III CRC patients treated with or
without cetuximab
A significant association was found between the chip
results, cetuximab treatment and clinical outcome that
51 patients with negative chip results received cetuximab





(N = 263 )
Total Sensitivity Specificity PPVc NPVd Accuracy P-value
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
WEnCAb
Positive 117 14 131 92.13% 94.68% 89.31% 96.14% 93.85% <0.001
Negative 10 249 259 (86.11-95.67%) (91.26-96.8%) (82.86-93.53%) (93.04-97.89%) (91.47-96.23%)
aKRAS in tumor tissues (direct sequencing).
bKRAS in peripheral blood (weighted enzymatic chip array; WEnCA).
cPPV: positive predictive value.
dNPV: negative predictive value.
95% CI: 95% confidence interval.
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(p = 0.047). On the other hand, 6 (75%) of the 8 patients
with positive chip results who chose to receive cetuximab
treatment, most had a relapse (6 patients, 75%) (Table 6).
Otherwise, no significant relationship was found in pa-
tients who were treated with FOLFOX-4 alone (p = 0.633).
Half of 6 patients with positive chip results who received
FOLFOX-4 alone had a relapse. Similarly, 16 (48.5%)
patients with positive chip results received FOLFOX-4
alone, and half of them had a relapse (Table 6).
Discussion
Previous studies [24,25] showed that the benefits of the
anti-EGFR mAb cetuximab among patients with metastatic
colorectal cancer are limited to those patients who have
colorectal tumor tissues with wild-type KRAS genes,
and KRAS genes with mutations are essentially insensitive
to EGFR inhibitors. In particular, KRAS genotyping of
primary tumor tissues or metastatic lesions is stronglyTable 5 The association between the mean positive gene
number and the mean positive total score by WEnCA and







Variables Total 117 46.86
Stage (AJCC)a
I + II 202 41 41.62 < 0.0001
III + IV 188 76 48.73
T stage
T1 + T2 193 75 43.93 < 0.0001
T3 + T4 197 42 50.37
Lymph node metastasis
No 187 50 47.67 0.177
Yes 203 67 46.64
Distant metastasis
No 297 79 41.21 0.009
Yes 93 38 54.72
a American Joint Committee on Cancer.recommended by the National Comprehensive Cancer
Network (NCCN) Clinical Practice Guidelines in Oncology
version 3 (2008) in patients with mCRC prior to any
therapy that includes anti-EGFR mAbs [26]. Therefore,
it is important to identify mCRC patients who harbor
KRAS mutants prior to the addition of such expensive
targeted therapies to standard chemotherapy.
KRAS genotyping highlights the value of banking tumor
specimens obtained from primary tumors or a metastasis.
In most of these studies, KRAS genotyping was performed
on primary colorectal cancers, whereas anti-EGFR anti-
bodies were used to treat the metastatic disease. This
strategy might, at least in certain circumstances, present
two limitations [27]. First, systematic KRAS genotyping in
metastatic colorectal cancer patients might be hampered
in the future, at least for some patients, by the difficulty of
obtaining tumor samples suitable for molecular analyses.
Second, considering the genetic heterogeneity of colorec-
tal cancers [28,29], the absence of detectable KRAS muta-
tions in the primary tumor may not formally exclude the
presence of a KRAS mutation in metastases, and conse-
quently, additional tumor samples need to be examined in
order for KRAS mutations to correctly predict the KRAS
status in metastatic lesions. Hence, an alternative method
for detecting KRAS gene mutations in these metastatic
colorectal cancer patients treated with anti-EGFR is needed.
We used this chip to detect the activating KRAS, not to
directly identify its mutation status. There are many
mutation sites on the KRAS gene, including codons 12,
13, 15, 18, and 31, among others, but while some muta-
tions activate KRAS, others do not. In our earlier reportsTable 6 The association between chemotherapy




WEnCA (N) Relapse No relapse P-value
N=42 (%) N = 46 (%)
FOLFOX-4 plus
Cetuximab (N = 59)
Positive (N = 8) 6 (75) 2 (25) 0.047
Negative (N = 51) 17 (33.3) 34 (66.7)
FOLFOX-4 (N = 29) Positive (N = 6) 3 (50) 3 (50) 0.633
Negative (N = 23) 16 (48.5) 7 (21.2)
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tions in codon 31 always showed negative results in this
chip assay. The possible reason for this finding is that
the mutation site of these codons cannot activate KRAS,
which may explain the discordance in KRAS status between
tumor and blood samples.
A previous study reported that KRAS mutations in a
tumor may not be detected in the bloodstream and sug-
gested that this non-detection may be caused by the low
DNA concentration, as well as the heterogeneity [30].
Since the principle of the Activating KRAS Detection
Chip is to detect the expression of multiple downstream
genes from KRAS, it could reveal the integral situation
of activating KRAS instead of detecting the status from a
single marker, which may be undetectable because of
detection limitations, and in this way also overcome
the heterogeneity issue.
Our recently developed membrane-array-based multi-
marker assay can detect activating KRAS mutations in
the circulating RNA in the peripheral blood of patients
with various malignancies, including colorectal cancer,
achieving considerable sensitivity, specificity, and accur-
acy when compared to the direct sequencing of tumor
tissues [19]. The results of the current study demonstrate
that WEnCA is a sensitive and convenient technique
for detecting activated KRAS from the peripheral blood
of NSCLC and CRC cancer patients. In fact, the sensitivity
of WEnCA reached 92.13% and the specificity reached
94.68% in this study, and the similar results which the sen-
sitivity, specificity, and accuracy were all above 92% in pre-
vious studies using WEnCA platform [31,32].
Although the Next Generation Sequencing (NGS) is
a rapidly developed high-throughput technique that
improves the sensitivity and reduces the cost of Sanger
sequencing, the difficulty in tumor tissue specimen
collection still cause the limitation for this method
[33]. Even NGS can be applied to RNA sequencing
using blood sample [34], the data analysis and inter-
pretation is quiet complicated especially compared
with WEnCA platform which is easy to interpret and
only needs basic calculation. Moreover, the overall cost
of NGS is higher than membrane-based WEnCA plat-
form currently.
The identification of activated KRAS status could be
extremely useful in selecting feasible CRC patients for
cetuximab therapy, allowing some patients to avoid un-
necessary treatment. In the present study, the relapse
rate was only 17/51 (33.3%) in stage III CRC patients
with negative chip results who received cetuximab ther-
apy; on the other hand, the rate was 75% among patients
with positive chip results. There were prominent associ-
ations between the chip results and relapse status, and
these associations could therefore be used as a pre-
cetuximab therapy predictor for clinical outcomes ofstage III CRC. This finding could be useful in the future
for identifying individual risk and developing alternative
therapeutic strategies.
Conclusions
This present study indicated that a panel of molecular
markers could be applied, in conjunction with our con-
structed membrane-array method with weighted calcu-
lation, to detect activating KRAS status from circulating
RNA in the peripheral blood of NSCLC and CRC patients.
The Activating KRAS Detection Chip using WEnCA
technique could also be a potential aid in clinical predic-
tions for obtaining better cetuximab response prediction
models. The results of the present study suggest that such
technique could be used to distinguish between CRC
patients who will respond to cetuximab treatment and
those who will not. That being said, further studies in-
volving larger sample sizes and even multiple centers
are needed to verify these results.
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